Clinical Study Protocol Amendment 1 (Version 2.0, dated 06 April 2018) was developed to: • Clarify that the patient population should be non-neutropenic and have invasive candidiasis; • Revise study design by shortening Study Drug Treatment Period from 42 days (6 weeks) to 14 days; • Revise study design by differentiating between EOST and an additional visit at EOT; • Revise secondary objectives to evaluate outcomes at these new timepoints (eg, EOST and EOT visits); • Clarify the acceptability of rapid diagnostic tests of blood samples for eligibility assessments; • Revise the definition of an inappropriate fungal infection source control within the exclusion criteria; • Expand the exclusion criteria to incorporate the “diagnosis of deep-seated Candida-related infections causing intraperitoneal candidiasis, septic arthritis, osteomyelitis, endocarditis, myocarditis, meningitis, or central nervous system infection or site of infection that would require antifungal treatment to exceed maximal duration of study drug (14 days)”; • Clarify the list of excluded concomitant medications to be efavirenz, nevirapine, phenobarbital, modafinil, nafcillin, St. John's Wort, and enzalutamide; • Allow further antifungal treatment (step-down therapy) with fluconazole (unless susceptibility results warranted alternative antifungal therapy) for up to a further 7 days if indicated, to adhere to the IDSA clinical practice guidelines for the treatment of candidiasis; • Specify a +2 day window to the 2-week follow-up visit after EOT; • Specify a +4 day window to the 4-week follow-up visit after EOT; • Change the window for study drug treatment visits from a minimum of ±2 days to a maximum of ±2 days; • Define bloodstream infection monitoring to be continued during Study Drug Treatment until 2 consecutive blood cultures were negative; • Add coagulation to the clinical laboratory parameters;

Clinical Study Protocol Amendment 2 (Version 3.0, dated 03 June 2019) was developed to: • Update the age range of patients for 18 to 80 years of age (inclusive) to ≥18 years of age; • Clarify instructions for the timing of fundoscopic examinations; • Clarify that the DRC determined Treatment Success; • Clarify the timing for collection of vital signs; • Remove the need to have study drug PO doses administered within 30 minutes of removing from refrigeration; • Add a PK plasma sample to EOST; • Clarify the collection of blood cultures for determination of Candida spp. infection: 2 consecutive sets (1 aerobic and 1 anaerobic blood culture bottle per set) of blood cultures from 2 separate sites (1 from a CVC and 1 peripheral venipuncture, or 2 peripheral venipunctures, if a CVC was not applicable); • Update the instructions for submitting local laboratory blood culture isolates to the central mycology reference laboratory for confirmation of spp. identification and antifungal susceptibility testing; and • Clarify that only outpatients would record daily PO dosing in a diary.